| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| James E. Flynn | Director | 2025-02-27 | 353,249 | $0.93 | $328.87kBuy |
| James E. Flynn | Director | 2025-02-27 | 353,249 | $0.93 | $328.87kBuy |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Orbimed Israel Biofund GP Limited Partnership | 902.22% | 13,773,653 | $65.70M | Insider |
| Erez Chimovits | 303.08% | 4,626,978 | $22.07M | Insider |
| Chidozie Ugwumba | 196.32% | 2,997,025 | $14.30M | Insider |
| James E. Flynn | 163.37% | 2,494,108 | $11.90M | Insider |
| Deerfield Management Company LP | 163.37% | 2,494,108 | $11.90M | Institution |
| Nantahala Capital Management LLC | 163.32% | 2,493,309 | $11.89M | Institution |
| Takeda Pharmaceutical Co Ltd | 161.85% | 2,470,935 | $11.79M | Insider |
| Jonas Grossman | 136.26% | 2,080,217 | $9.92M | Insider |
| Fibrosis Foundation Cystic | 117.10% | 1,787,758 | $8.53M | Insider |
| Alyeska Investment Group LP | 104.20% | 1,590,738 | $7.59M | Institution |